[WT1 gene expression in patients with acute myelogenous leukemia or high risk myelodysplastic syndrome successfully treated with the CAG regimen].

Abstract

Ten patients with acute myelogenous leukemia or high risk myelodysplastic syndrome who had achieved complete remission following treatment with the CAG regimen were monitored for peripheral blood WT1 expression mRNA levels. Induction therapy with the CAG regimen did not seem to be enough to lower WT1 expression levels to the normal range. In comparison with patients who received intensive chemotherapy for post-remission therapy, those who received only CAG therapy showed higher levels of WT1 expression and more easily relapsed. These data suggest that CAG therapy alone might not be sufficient to maintain complete remission and WT1 monitoring could be useful in the choice of appropriate post-remission therapy after achieving remission with the CAG regimen.

• Authors: Yuko Nakamura, Yukihiro Arai, Hisako Gunji, Honoka Arai, Fumihiko Nakamura, Tomoyuki Handa, Jiro Tadokoro, Kazuhiro Maki, Kenji Saito, Kinuko Mitani
• Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 43 Issue 10 Pg. 960-2 (Oct 2002) ISSN: 0485-1439 [Print] Japan
• PMID: 12462034 (Publication Type: English Abstract, Journal Article)

Chemical References

• WT1 Proteins
• Cytarabine
• Granulocyte Colony-Stimulating Factor
• Aclarubicin

Topics

• Aclarubicin (administration & dosage)
• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
• Cytarabine (administration & dosage)
• Drug Administration Schedule
• Female
• Granulocyte Colony-Stimulating Factor (administration & dosage)
• Humans
• Leukemia, Myeloid, Acute (drug therapy, metabolism)
• Male
• Middle Aged
• Myelodysplastic Syndromes (drug therapy, metabolism)
• Remission Induction
• WT1 Proteins (genetics)